Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Safran

Showing results (51-60 of 117) with videos related to

Pageof 12
Sort By:
American Journal of Clinical Oncology|November 3, 2015
FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I StudyHoward Safran, Kevin P Charpentier, Kimberly Perez, et al.
American Journal of Clinical Oncology|December 1, 2005
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I studyDavid Iannitti, Tom Dipetrillo, Paul Akerman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2008
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704Adam C Berger, Miguel Garcia, John P Hoffman, et al.
American Journal of Clinical Oncology|September 30, 2009
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysisAriel Birnbaum, Thomas Dipetrillo, Ritesh Rathore, et al.
Oncotargets and Therapy|September 15, 2012
Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancerTyvin A Rich, Kathryn Winter, Howard Safran, et al.
The Oncologist|March 18, 2016
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid TumorsAnthony J Olszanski, David C Smith, Luis H Camacho, et al.
International Journal of Radiation Oncology, Biology, Physics|June 12, 2012
Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trialAdam C Berger, Kathryn Winter, John P Hoffman, et al.
Frontiers in Oncology|June 6, 2012
A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung CancerHumera Khurshid, Thomas Dipetrillo, Thomas Ng, et al.
International Journal of Radiation Oncology, Biology, Physics|November 6, 2007
Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicityHoward Safran, Mohan Suntharalingam, Thomas Dipetrillo, et al.
Annals of Surgical Oncology|April 19, 2011
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trialWilliam F Regine, Kathryn A Winter, Ross Abrams, et al.
Pageof 12

Showing results (51-60 of 117) with videos related to

Sort By:
Pageof 12
American Journal of Clinical Oncology|November 3, 2015
FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I StudyHoward Safran, Kevin P Charpentier, Kimberly Perez, et al.
American Journal of Clinical Oncology|December 1, 2005
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I studyDavid Iannitti, Tom Dipetrillo, Paul Akerman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2008
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704Adam C Berger, Miguel Garcia, John P Hoffman, et al.
American Journal of Clinical Oncology|September 30, 2009
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysisAriel Birnbaum, Thomas Dipetrillo, Ritesh Rathore, et al.
Oncotargets and Therapy|September 15, 2012
Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancerTyvin A Rich, Kathryn Winter, Howard Safran, et al.
The Oncologist|March 18, 2016
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid TumorsAnthony J Olszanski, David C Smith, Luis H Camacho, et al.
International Journal of Radiation Oncology, Biology, Physics|June 12, 2012
Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trialAdam C Berger, Kathryn Winter, John P Hoffman, et al.
Frontiers in Oncology|June 6, 2012
A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung CancerHumera Khurshid, Thomas Dipetrillo, Thomas Ng, et al.
International Journal of Radiation Oncology, Biology, Physics|November 6, 2007
Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicityHoward Safran, Mohan Suntharalingam, Thomas Dipetrillo, et al.
Annals of Surgical Oncology|April 19, 2011
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trialWilliam F Regine, Kathryn A Winter, Ross Abrams, et al.
Pageof 12